Pre-made Ibalizumab benchmark antibody ( Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ibalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ibalizumab (trade name Trogarzo) is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a sub-class of HIV drugs called entry inhibitors.
| Products Name (INN Index) | Pre-Made Ibalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody |
|---|---|
| INN Name | Ibalizumab |
| Target | CD4 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 3o2d:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2007 |
| Year Recommended | 2008 |
| Companies | Biogen Idec,TaiMed Biologics,Theratechnologies |
| Conditions Approved | HIV-1 infections |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD4 |
| Package |
